Home » Stocks » CNTB

Connect Biopharma Holdings Limited (CNTB)

Stock Price: $17.00 USD 0.60 (3.66%)
Updated Apr 9, 2021 4:00 PM EDT - Market closed
Market Cap 948.88M
Revenue (ttm) n/a
Net Income (ttm) -119.15M
Shares Out 55.82M
EPS (ttm) -2.13
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day April 9
Last Price $17.00
Previous Close $16.40
Change ($) 0.60
Change (%) 3.66%
Day's Open 16.52
Day's Range 16.22 - 17.15
Day's Volume 12,718
52-Week Range 15.29 - 23.29

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

NEW YORK--(BUSINESS WIRE)--Deutsche Bank announced today its appointment as depositary bank for the Nasdaq-listed American Depositary Receipt program of Connect Biopharma Holdings Limited. Connect Bioph...

2 weeks ago - Business Wire

SAN DIEGO and TAICANG, China, March 23, 2021 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (the “Company”), a global clinical-stage biopharmaceutical company dedicated to improvi...

2 weeks ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, FNCH, GANX, JWEL, NAPA, OLO, SNCY ...
2 weeks ago - Benzinga

SHANGHAI, March 19, 2021 /PRNewswire/ -- Qiming Venture Partners' portfolio company Connect Biopharma today listed on the Nasdaq with the stock code "CNTB". The issue price is US$ 17.00/ADS.

3 weeks ago - PRNewsWire

SAN DIEGO and TAICANG, China, March 18, 2021 -- Connect Biopharma Holdings Limited (the “Company”), a global clinical-stage...

3 weeks ago - GlobeNewswire

Connect Biopharma Holdings, a Chinese Phase 2 biotech developing therapies for T cell-driven inflammatory diseases, filed on Friday with the SEC to raise up to $100 million in an initial public offering.

1 month ago - NASDAQ

Connect Biopharma Holdings Limited has filed to go public with an IPO on the NASDAQ.

1 month ago - SEC

About CNTB

Connect Biopharma is a global clinical-stage biopharmaceutical company developing therapies for the treatment of inflammatory diseases with significant unmet medical need. We specialize in designing and developing product candidates that modulate the immune system, with a particular focus on T cells. Our lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha which is a validated target for the treatment of inflammatory diseases such as atopic dermatitis, or AD, and asthma. We have initiated a Phase 2b tr... [Read more...]

Industry
Pharmaceutical Preparations
IPO Date
Mar 19, 2021
CEO
Zheng Wei, Ph.D.
Employees
62
Stock Exchange
NASDAQ
Ticker Symbol
CNTB
Full Company Profile

Financial Performance

Financial numbers in millions CNY.
Financial Statements